期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 43, 期 5, 页码 288-295出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2016.01.005
关键词
Trithiol ligand; Arsenic trithiol; No carrier added As-77; Radiolabeling; Crystal structures
资金
- US Department of Energy, Office of Science, Isotope Research Program [DE-SC0003851, DE-SC0010283]
- NIBIB [5 T32-EB004822]
- U.S. Department of Energy (DOE) [DE-SC0010283] Funding Source: U.S. Department of Energy (DOE)
Introduction: Arsenic-72 (As-72; 2.49 MeV beta(+), 26 h) and As-77 (0.683 MeV beta(-), 38.8 h) have nuclear properties useful for positron emission tomography (PET) and radiotherapy applications, respectively. Their half-lives are sufficiently long for targeting tumors with antibodies, as well as peptides. Potential radiopharmaceuticals based on radioarsenic require development of suitable bifunctional chelates for stable conjugation of arsenic to vectors under in vivo conditions at high dilution. Methods: The thiophilic nature of arsenic led to the synthesis and characterization of a simple trithiol ligand and its arsenic complex, and radiolabeling studies at the no carrier added (NCA) As-77 level. Results: H-1- and C-13-NMR spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and single crystal X-ray diffraction were used to characterize the trithiol ligand and its arsenic(III) complex. Radiotracer studies with no carrier added (NCA) As-77 resulted in high radiolabeling yields (>96%) with high in vitro stability. Conclusions: The high yield and stability of a single NCA As-77 trithiol complex indicates that this framework is suitable for developing matched pair agents for non-invasive in vivo PET imaging and radiotherapy of tumors with (72,77)AS. This is the first reported chelate developed for NCA radioarsenic and studies are underway for developing a trithiol bifunctional chelate conjugated to a targeting vector, such as a peptide or monodonal antibody. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据